EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA – February 28, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2023. Fourth Quarter Highlights ● Net revenues of $178.1 million for the fourth quarter ● GAAP net income ...

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $51.91, moving +1.29% from the previous trading session. This change lagged the S&P 500's 2.11% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 2.96%.Shares of the specialty pharmaceutical company witnessed a loss of 7.19% over the previous month, trailing the performance of the Medical sector with its gain of 3.98% and the S&P 500's gain of 3.08%.Market participants will be closely following t ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Amphastar Pharmaceuticals (AMPH) .Amphastar currently has an average broke ...

Drug stock Amphastar Pharmaceuticals (AMPH) has formed a cup base and settled down after a steep sell-off in January. Now, as an IBD Sector Leader, Amphastar stock is about 18% off its all-time high.X Amphastar develops injectable, inhalation and intranasal medical and insulin products. Its products are used mainly in hospitals and urgent care clinics. It also makes over-the-counter asthma inhaler Primatene Mist, along with emergency glucagon treatment kits for low blood sugar.Amphastar ranks No. 1 among 75 ...

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.61, moving +1.85% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.57%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 1.25%.Prior to today's trading, shares of the specialty pharmaceutical company had gained 1.05% over the past month. This has lagged the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.Investors will be eagerly watching for the per ...

The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.Nkarta (NKTX) ...

Amphastar Pharmaceuticals (AMPH) closed at $54.94 in the latest trading session, marking a -0.81% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.06%. At the same time, the Dow added 0.35%, and the tech-heavy Nasdaq lost 0.76%.Shares of the specialty pharmaceutical company witnessed a loss of 10.45% over the previous month, trailing the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 3.36%.Analysts and investors alike will be keepi ...

The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve’s monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market.The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists’ forec ...

Toward the end of 2023, the economy started showing signs of stabilization and easing inflationary pressure as the Fed finally decided to keep interest rates unchanged. This is likely to benefit generic drugmakers like Amphastar Pharmaceuticals (AMPH) , Teva Pharmaceutical (TEVA) and Dr. Reddy’s Laboratories (RDY) , who can potentially benefit from declining costs in the long run.These drugmakers are also focusing on new product launches or existing products with high gross margins to support their top and ...

Investors seeking healthy returns should add stocks with favorable liquidity to their portfolios.Liquidity measures a company’s capability to meet its short-term debt obligations. Stocks with high liquidity levels have always been in demand, owing to their potential to provide maximum returns.Investors should be alert before considering such stocks. While a high liquidity level may imply that the company is clearing its dues faster than its peers, it may also suggest that it cannot utilize assets competentl ...